First‐in‐human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2025 at "Cancer"
DOI: 10.1002/cncr.35939
Abstract: Indoleamine 2,3‐dioxygenase 1 (IDO1) is a heme‐containing enzyme that degrades tryptophan (Trp) to kynurenine (Kyn), which suppresses effector T cells and reduces antitumor activity. KHK2455 is a long‐acting selective IDO1 inhibitor that blocks the heme… read more here.
Keywords: solid tumors; first human; combination mogamulizumab; mogamulizumab patients ... See more keywords
Successful treatment of mogamulizumab‐resistant mycosis fungoides with mogamulizumab plus etoposide combined therapy: Investigation of the immunomodulatory effects of etoposide on the tumor microenvironment
Sign Up to like & getrecommendations! Published in 2020 at "Dermatologic Therapy"
DOI: 10.1111/dth.13487
Abstract: Mogamulizumab shows cytotoxicity against CCR4+ lymphoma cells by antibody‐dependent cell‐mediated cytotoxicity (ADCC) in advanced cutaneous T‐cell lymphoma (CTCL) patients. Although mogamulizumab is used as one of the anchor drugs for the treatment of advanced CTCL,… read more here.
Keywords: successful treatment; treatment; mycosis fungoides; mogamulizumab ... See more keywords
Mogamulizumab Tops Standard of Care for CTCL.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2018-001
Abstract: In the large international phase III MAVORIC trial, patients with previously treated cutaneous T-cell lymphoma who received the anti-CCR4 monoclonal antibody mogamulizumab experienced significantly longer progression-free survival and higher response rates, as well as better… read more here.
Keywords: mogamulizumab tops; mogamulizumab; standard care; tops standard ... See more keywords
Efficacy and manageable toxicity of mogamulizumab in a real-world North American cohort of adult T-cell leukemia/lymphoma (ATLL).
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e18603
Abstract: e18603 Background: Adult T-cell leukemia/lymphoma (ATLL), a malignancy of CD4+ T-cells linked to HTLV-1 infection, carries a poor prognosis. Treatment options beyond allogeneic transplantation remain limited. Mogamulizumab, a CCR4-targeting monoclonal antibody, is FDA-approved for relapsed… read more here.
Keywords: treatment; cohort; real world; atll ... See more keywords
Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection
Sign Up to like & getrecommendations! Published in 2020 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s185896
Abstract: Abstract Advanced cutaneous T cell lymphomas (CTCL) including mycosis fungoides (MF) and Sézary syndrome (SS) are often difficult to manage once they become resistant to initial systemic treatment. Current systemic treatments usually provide a limited… read more here.
Keywords: mogamulizumab; zary syndrome; treatment; fungoides zary ... See more keywords
Mogamulizumab Concentration-guided Allogeneic Transplantation and Successful Intrathecal Chemotherapy for Central Nervous System-relapsed Adult T-cell Leukemia/Lymphoma.
Sign Up to like & getrecommendations! Published in 2025 at "Internal medicine"
DOI: 10.2169/internalmedicine.5598-25
Abstract: Adult T-cell leukemia/lymphoma (ATL) has a poor prognosis, with mogamulizumab effectively controlling the disease but increasing graft-versus-host disease (GVHD) risk during transplantation if residual levels persist. We herein report a 61-year-old patient with acute-type ATL… read more here.
Keywords: intrathecal chemotherapy; leukemia lymphoma; adult cell; mogamulizumab ... See more keywords
Mogamulizumab and bexarotene are a promising association for the treatment of advanced cutaneous T-cell lymphomas: a case series.
Sign Up to like & getrecommendations! Published in 2022 at "European review for medical and pharmacological sciences"
DOI: 10.26355/eurrev_202211_30166
Abstract: BACKGROUND Treatment choices for patients with advanced-stage mycosis fungoides (MF) or Sézary syndrome (SS) who have failed first-line systemic therapies can be challenging, as several options are available. However, most evidence is based on observational… read more here.
Keywords: mogamulizumab; bexarotene; treatment; bexarotene promising ... See more keywords
Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14071659
Abstract: Simple Summary Mogamulizumab is a recent monoclonal antibody prescribed in the second line to treat advanced mycosis fungoides and Sézary syndromes. We collected data from all patients who used mogamulizumab in six French university hospitals… read more here.
Keywords: mogamulizumab; real life; progression; cell lymphomas ... See more keywords